David P Schenkein Denali Therapeutics Inc. (DNLI) insider trading activity

David P Schenkein is Director of Denali Therapeutics Inc.. Currently has a direct ownership of 15,257 shares of DNLI, which is worth approximately $211,614. The most recent transaction as insider was on Jun 03, 2025, when has been sold 6,037 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 15.3K

65.48% 3M change

29.02% 12M change

Total Value Held $211,614

David P Schenkein Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 03 2025	BUY Grant, award, or other acquisition	-	6,037 Added 28.35%	15,257 Common Stock
Nov 11 2024	SELL Open market or private sale	$1,930,643 $32.48 p/Share	59,441 Reduced 86.57%	9,220 Common Stock
Nov 11 2024	BUY Exercise of conversion of derivative security	$848,970 $18.0 p/Share	47,165 Added 40.72%	68,661 Common Stock
May 31 2024	BUY Grant, award, or other acquisition	-	5,967 Added 21.73%	21,496 Common Stock
Jun 01 2023	BUY Grant, award, or other acquisition	-	4,216 Added 21.35%	15,529 Common Stock
Jun 02 2022	BUY Grant, award, or other acquisition	-	5,986 Added 34.6%	11,313 Common Stock
Jun 02 2021	BUY Grant, award, or other acquisition	-	2,074 Added 28.02%	5,327 Common Stock
Jun 01 2021	BUY Exercise of conversion of derivative security	-	3,253 Added 50.0%	3,253 Common Stock
Dec 21 2020	SELL Open market or private sale	$2,251,500 $90.06 p/Share	25,000 Reduced 100.0%	0 Common Stock
Nov 12 2020	SELL Open market or private sale	$2,101,500 $70.05 p/Share	30,000 Reduced 54.55%	25,000 Common Stock
Nov 10 2020	SELL Open market or private sale	$600,300 $60.03 p/Share	10,000 Reduced 15.38%	55,000 Common Stock
Nov 04 2020	SELL Open market or private sale	$501,800 $50.18 p/Share	10,000 Reduced 13.33%	65,000 Common Stock

Also insider at

REGN

REGENERON PHARMACEUTICALS, INC. Healthcare

Director

AGIO

AGIOS PHARMACEUTICALS, INC. Healthcare

Director

PRME

Prime Medicine, Inc.

Director

DPS